CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS
about
γδ T Cells and NK Cells - Distinct Pathogenic Roles as Innate-Like Immune Cells in CNS AutoimmunityTherapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosisCutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple SclerosisA critical appraisal of daclizumab use as emerging therapy in multiple sclerosis.Daclizumab for the treatment of multiple sclerosis.Monoclonal Antibodies for Relapsing Multiple Sclerosis: A Review of Recently Marketed and Late-Stage Agents.Human CD56bright NK Cells: An Update.Increased prevalence of lymphoid tissue inducer cells in the cerebrospinal fluid of patients with early multiple sclerosis.Daclizumab: A Review in Relapsing Multiple Sclerosis.Identifying targets for diagnosis, prognosis, and treatment.Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis.Anti-CD25 monoclonal antibody Fc variants differentially impact regulatory T cells and immune homeostasis.Population PK-PD analyses of CD25 occupancy, CD56bright NK cell expansion, and regulatory T cell reduction by daclizumab HYP in subjects with multiple sclerosis.Programmed cell death and natural killer cells in multiple sclerosis: new potential therapeutic targets?Daclizumab.Drugs approved for the treatment of multiple sclerosis: review of their safety profile.Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis.No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.Daclizumab Therapy for Multiple Sclerosis.Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy in MS
P2860
Q26781330-A7F76583-E3DE-4074-8FE9-679170BB6B2EQ28066677-493DBF1F-6C63-47F0-BD63-22944C114B7CQ37080630-8C88A712-F781-41EB-85DE-C36BFFF068FCQ38397484-F905AAC2-4791-43CC-A39D-3817EABD9272Q38604207-8CD75BD1-75B1-46F7-A1D6-9371E6F178ECQ38747100-2CF49294-F034-48D3-ABB6-CE6A9E63AE85Q38781384-4AC1FFF4-8635-4474-AE29-07343BF0A8E9Q38954794-EFD069F0-F7D9-4BA8-B507-C43466DA240FQ39140303-15820BED-884F-46A8-9227-5E3C9CDB86FBQ39285612-035B75D7-C7DB-4F21-8008-D73E0DB624A6Q39434495-A6F60001-D788-45A5-AF87-0A9E49DC6344Q39890899-7EE2B99A-C323-4EF5-A604-6718056B5E82Q42700892-0DEF66DE-EAB5-4E9C-BA53-6CB6D2CB8AC0Q42732611-650BFCCD-4496-4295-8D6D-0D0D039FC1EBQ46487963-0FE8AF00-DAF1-4568-AA91-A5FC78A68020Q47868767-4943372B-237D-4FC0-BA93-57275886356AQ47959279-AAF57088-D68E-4440-8155-4A6F891B468CQ50956425-BEC1B744-8EA7-43F0-A925-63429E94ACB3Q52319805-CE5F299E-C378-4BD8-9298-1097376A1E26Q56963530-AA896034-A38A-45F3-AD79-65DD00CC6F75
P2860
CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
CD56(bright) natural killer ce ...... HYP in relapsing-remitting MS
@ast
CD56(bright) natural killer ce ...... HYP in relapsing-remitting MS
@en
type
label
CD56(bright) natural killer ce ...... HYP in relapsing-remitting MS
@ast
CD56(bright) natural killer ce ...... HYP in relapsing-remitting MS
@en
prefLabel
CD56(bright) natural killer ce ...... HYP in relapsing-remitting MS
@ast
CD56(bright) natural killer ce ...... HYP in relapsing-remitting MS
@en
P2093
P2860
P1476
CD56(bright) natural killer ce ...... HYP in relapsing-remitting MS
@en
P2093
B Bielekova
G Giovannoni
J Sheridan
L Amaravadi
P2860
P356
10.1212/NXI.0000000000000065
P577
2015-01-22T00:00:00Z